奥赛康:公司一类创新药利厄替尼片(奥壹新 )近日在国际顶级医学期刊《柳叶刀.呼吸病学》(IF:32.8)发布该产品的III期临床研究结果。利厄替尼片是第三代表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI),用于具有EGFR突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线、二线治疗。百奥泰:公司与SteinCares签署授权许可及生产、供货和商业化协议,将BAT2406注射液在...
Source Link奥赛康:公司一类创新药利厄替尼片(奥壹新 )近日在国际顶级医学期刊《柳叶刀.呼吸病学》(IF:32.8)发布该产品的III期临床研究结果。利厄替尼片是第三代表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI),用于具有EGFR突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线、二线治疗。百奥泰:公司与SteinCares签署授权许可及生产、供货和商业化协议,将BAT2406注射液在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.